Wednesday was a good day for American stocks generally, but it was even sunnier for Eli Lilly<\/strong> (NYSE: LLY)<\/span>. The pharmaceutical giant won regulatory approval for a product that’s bound to be very popular, and investors rewarded the company by pushing its stock nearly 4% higher on the day. That crushed the S&P 500<\/strong> index’s 0.7% gain.<\/p>\n Before market open, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) approved its Foundayo weight-loss product. What makes this groundbreaking for the company is that Foundayo is a daily pill. The pharmaceutical titan’s first approved weight-loss drug, the popular Zepbound, is delivered by injection once per week. The two also use different molecules to do their work.<\/p>\n Will AI create the world’s first trillionaire?<\/strong>\u00a0Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need.\u00a0Continue \u00bb<\/strong><\/span><\/em><\/p>\n The freshly approved drug will start shipping starting next Monday, April 6, through the company’s proprietary LillyDirect online sales platform. Self-pay options start at $149 monthly for the lowest Foundayo dose.<\/p>\n “As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world,” Eli Lilly quoted its CEO, David Ricks, as saying.<\/p>\n Foundayo’s inevitably going to be compared to the Wegovy pill, the recently FDA-approved obesity product from Novo Nordisk<\/strong>. Would-be patients have to weigh several factors. In Foundayo’s favor, its molecule is sturdier, and the drug can be taken anytime, unlike the more delicate Wegovy pill. Yet the latter has reported higher weight-loss figures in clinical testing than the former.<\/p>\n Yet we should remember that Eli Lilly is massive and has vast resources to market the heck out of Foundayo. By contrast, Novo Nordisk is more limited. So I think we’ll see significant take-up of Eli Lilly’s new drug, and an accompanying lift in share price.<\/p>\n Before you buy stock in Eli Lilly, consider this:<\/p>\n The Motley Fool Stock Advisor<\/em> analyst team just identified what they believe are the\u00a010 best stocks<\/strong> for investors to buy now\u2026 and Eli Lilly wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix<\/strong> made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $518,530<\/strong>!* Or when Nvidia<\/strong> made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,069,165<\/strong>!*<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>